Drugs Made In America Acquisition II Corp Unit
DMIIU
14 hedge funds and large institutions have $43.5M invested in Drugs Made In America Acquisition II Corp Unit in 2026 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 4 reducing their positions, and 17 closing their positions.
14.14% less ownership
Funds ownership: 22.64% → 8.5% (-14%)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
53% less funds holding
Funds holding: 30 → 14 (-16)
63% less capital invested
Capital invested by funds: $116M → $43.5M (-$72.6M)
75% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 4
94% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 17
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KC
Kepos Capital
New York
|
+$2.11M |
| 2 |
RC
Rangeley Capital
New Canaan,
Connecticut
|
+$232K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MI
MMCAP International
Grand Cayman,
Cayman Islands
|
-$27M |
| 2 |
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Toronto,
Ontario, Canada
|
-$20M |
| 3 |
HCM
Heights Capital Management
San Francisco,
California
|
-$5.19M |
| 4 |
Millennium Management
New York
|
-$5.01M |
| 5 |
RCM
Rivernorth Capital Management
West Palm Beach,
Florida
|
-$4.01M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
PCM
26
Prelude Capital Management
New York
| – | -$501K | -50,000 | Closed |
|
|
SPCM
27
Stoic Point Capital Management
Palo Alto,
California
| – | -$501K | -50,000 | Closed |
|
|
PCM
28
PenderFund Capital Management
Vancouver,
British Columbia, Canada
| – | -$497K | -49,700 | Closed |
|
29
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$251K | -25,112 | Closed |
|
|
BFM
30
Boothbay Fund Management
New York
| – | -$250K | -25,000 | Closed |
|
31
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
| – | -$5.45K | -544 | Closed |
|
DMIIU Hedge Fund Activity: Q1 2026 in Review
14 of the 8,172 institutional investors tracked by Wall St. Rank reported a position in Drugs Made In America Acquisition II Corp Unit (DMIIU) for Q1 2026, worth a combined $43.5M — down 63% from $116M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of DMIIU and 1 opened new positions — a net loss of 16 holders — while 4 trimmed existing stakes and 1 added.
The largest buyer was Kepos Capital, opening a new position worth an estimated $2.11M. The largest seller was MMCAP International, exiting entirely with an estimated $27M sold.
- 14 institutional investors held Drugs Made In America Acquisition II Corp Unit (DMIIU) as of Q1 2026, down from 30 in Q4 2025.
- Funds reported $43.5M of Drugs Made In America Acquisition II Corp Unit stock for Q1 2026, down 63% quarter-over-quarter.
- 1 fund opened new Drugs Made In America Acquisition II Corp Unit positions in Q1 2026 and 17 closed out, a net change of -16 holders.
- The largest Drugs Made In America Acquisition II Corp Unit buyer in Q1 2026 was Kepos Capital, an estimated $2.11M added.
- The largest Drugs Made In America Acquisition II Corp Unit seller in Q1 2026 was MMCAP International, an estimated $27M sold.
Based on aggregated 13F filings for Q1 2026.